4D Molecular Therapeutics, Inc. Common Stock vs. Krystal Biotech, Inc. Common Stock
FDMT
4D Molecular Therapeutics, Inc. Common Stock
$15.59 +1.30%
VS KRYSKrystal Biotech, Inc. Common Stock
$351.03 +2.72%
Krystal Biotech, Inc. Common Stock (KRYS) comes out ahead, leading on 6 of 8 compared factors.
Size & Scale
| FDMT | KRYS | |
|---|---|---|
| Market Cap | $850.21 million | $10.11 billion |
| Revenue (TTM) | $92.01 million | $440.48 million |
| Net Income (TTM) | $-179,175,000 | $241.47 million |
KRYS leads on 3 of 3 size & scale factors.
Valuation
| FDMT | KRYS | |
|---|---|---|
| P/E Ratio | — | 43.99 |
| Price / Book | 2.09 | 7.44 |
| Price / Sales | 9.24 | 22.96 |
FDMT leads on 2 of 2 valuation factors.
Profitability
| FDMT | KRYS | |
|---|---|---|
| Net Margin | -194.74% | 54.82% |
| Return on Equity | -43.95% | 17.77% |
KRYS leads on 2 of 2 profitability factors.
Risk & Sentiment
| FDMT | KRYS | |
|---|---|---|
| Short Interest | 0.41% | 0.11% |
KRYS leads on 1 of 1 risk & sentiment factors.
Dig deeper: FDMT overview, FDMT financials, KRYS overview, KRYS financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.